Compare FORM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | PRAX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.3B |
| IPO Year | 2002 | 2020 |
| Metric | FORM | PRAX |
|---|---|---|
| Price | $148.44 | $286.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $138.63 | ★ $638.68 |
| AVG Volume (30 Days) | ★ 965.4K | 357.8K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.88 | N/A |
| Revenue Next Year | $17.12 | $39,590.54 |
| P/E Ratio | $146.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.14 | $50.31 |
| 52 Week High | $160.27 | $392.70 |
| Indicator | FORM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 70.82 | 35.63 |
| Support Level | $113.14 | $282.35 |
| Resistance Level | $158.56 | $354.17 |
| Average True Range (ATR) | 5.71 | 14.63 |
| MACD | 3.76 | -1.65 |
| Stochastic Oscillator | 94.09 | 21.96 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.